News
MyChesCo on MSN7h
ENHERTU plus Pertuzumab Shows Significant Progress in First-Line Treatment for HER2-Positive Breast CancerThe Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® ...
It holds the only FDA-cleared platform for CTC capture in metastatic breast cancer. Low competition in this modality ... One strategic partner (e.g. AstraZeneca) converts to exclusive user/licensee.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback